Reuters logo
3 个月内
BRIEF-Foamix Pharmaceuticals announces plans for additional phase 3 trial for FMX101 in moderate to severe acne
2017年5月1日 / 晚上8点52分 / 3 个月内

BRIEF-Foamix Pharmaceuticals announces plans for additional phase 3 trial for FMX101 in moderate to severe acne

1 分钟阅读

May 1 (Reuters) - Foamix Pharmaceuticals Ltd:

* Foamix Pharmaceuticals announces plans for additional phase 3 trial for fmx101 in moderate to severe acne

* Foamix Pharmaceuticals ltd- commencement of 3(rd) phase 3 trial planned mid 2017; submittal of nda planned in h2-2018

* Foamix pharmaceuticals announces plans for additional phase 3 trial for fmx101 in moderate to severe acne

* Foamix pharmaceuticals ltd- pooled analyses of phase 3 data show additional statistically significant effects on primary and secondary efficacy endpoints

* Foamix pharmaceuticals - if results will be positive, trial is expected to form basis for a nda which company plans to submit in second half of 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below